$10.7MSeries A, 25 February 2026
Funds the SAPPHIRE US pivotal trial of VisiPlate and pipeline work.
- Amount
- $10.7M
- Stage
- Series A
- Announced
- 25 February 2026
- Lead
- MedVenture Partners
- Other investors
- Good Growth Capital, Accanto Partners, Life Sciences Greenhouse, Quaker Capital
- Use of funds
- Funds the SAPPHIRE US pivotal trial of VisiPlate and pipeline work.
- Checked
- Announced by the company
- Sources
- Avisi Technologies announces $10.7M raise for glaucoma device vcaonline.com
Avisi Technologies announces $10.7M raise for glaucoma device prnewswire.com